Melatonin Levels on COVID-19 Positive Pregnant Women

Pregnancy Related Clinical Trial

Official title: Prognostic Value of Serum Melatonin as a Biomarker for the Determination of Severe COVID-19 Infection in Pregnant Women

Status Completed

Clinical Trial Summary

This study aimed to investigate the prognostic value of serum melatonin as a biomarker for the determination of severe COVID-19 infection in pregnant women. Four study groups were formed, including pregnant women with a positive COVID-19 PCR test, severe symptoms, and inpatient treatment. Pregnant women who had complaints similar to COVID-19 infection or had no complaints, but had a PCR test due to the surveillance program and negative test results were included in the control group. Methods and Main Outcome measure: Laboratory values of the cases at the time of diagnosis parameters were collected. Melatonin levels decrease in pregnant women with COVID-19 symptoms, the severity of symptoms increases. In addition, patients with low melatonin levels have an increase in infection parameters and an increase in the hospital stay.

Clinical Trial Description

A total of 228 pregnant women included in this prospective controlled study between June 20021 and June 2022 at Gynecology and Obstetrics Department of Health Sciences University Samsun Training and Research Hospital. ;

Related Conditions & MeSH terms

• Acute Lung Injury
• COVID-19
• Pregnancy Complications
• Pregnancy Related
• Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Newborn

• NCT number: NCT05318144
• Study type: Observational [Patient Registry]
• Source: Cumhuriyet University
• Status: Completed
• Start date: June 1, 2021
• Completion date: February 1, 2022